Skip to content

Vasculogenic Mimicry in Urothelial Carcinoma

Vasculogenic Mimicry in Urothelial Carcinoma and Its Association With Clinicopathologic Features

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04295967
Enrollment
70
Registered
2020-03-05
Start date
2020-05-31
Completion date
2022-05-31
Last updated
2020-03-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urothelial Carcinoma

Brief summary

In this study, the investigators aim at: 1. Evaluate the presence of vasculogenic mimicry in urothelial carcinomas by CD31-PAS double staining. 2. Correlate the presence of vasculogenic mimicry with the clinicopathologic features as age, sex, TNM stage, pathological grade, recurrence, carcinoma in situ, lymphovascular emboli, lymph node metastasis, necrosis, surgical margin, multifocality and tumor size in urothelial carcinoma.

Detailed description

Bladder cancer is the ninth most common cancer worldwide which seriously affects human health. In Egypt, it is the third common malignant tumor. Urothelial carcinoma (UC) is considered the most common histologic type of bladder cancer. It is well recognized that the biological behavior of several cancers is closely related to their blood supply. Tumor progression and metastasis have been long associated with tumor angiogenesis. However, several studies demonstrated that vascular targeting drugs which induce endothelial cell apoptosis have a little effect. So, it has been suggested that novel tumor microcirculation patterns may exist in these neoplasms. Vasculogenic mimicry (VM), is a novel tumor microcirculation system. Maniotis et al initially discovered VM in melanoma and defined these channels to be composed of tumor basement membrane lined externally by tumor cells, lacking blood vessel endothelium and containing plasma and red blood cells. So VM can be distinguished using immunohistochemical (IHC) staining and histochemical double staining. VM is CD31- or CD34-negative (endothelial markers) and periodic acid-Schiff (PAS) positive. Vasculogenic mimicry was detected in several malignant tumors. Several studies reported that VM can promote tumor progression and metastasis and it is positively associated with pathological grade, stage, recurrence and drug resistance. Previous studies which evaluate, the role of VM in urothelial carcinoma yield controversial results. So, the value of VM in urothelial carcinomas and its relation to the clinicopathologic parameters remains to be elucidated.

Interventions

OTHERformalin fixed paraffin embedded blocks

The study will be conducted using formalin fixed paraffin embedded blocks of seventy cases of urothelial carcinomas .CD31-PAS dual-staining will be performed to confirm the presence of VM.

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL

Inclusion criteria

* \- Specimens of urothelial carcinoma.

Exclusion criteria

* \- Any criteria that not fulfill the inclusion criteria such as resected urinary bladder tumors other than urothelial carcinoma.

Design outcomes

Primary

MeasureTime frame
Evaluate the presence of vasculogenic mimicry in urothelial carcinomas by CD31-PAS double stainingbaseline

Secondary

MeasureTime frame
Correlate the presence of vasculogenic mimicry with the clinicopathologic features in urothelial carcinoma.baseline

Contacts

Primary ContactEreny K Louis, demonstrator
ereny.kamal14@yahoo.com+201023720295

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026